Business Wire

ShadowDragon Sets a New Standard in Link Analysis, Monitoring, & OSINT by Launching Multilingual Suite

10.2.2025 16:21:00 CET | Business Wire | Press release

Share

ShadowDragon Horizon - Empowering Global Investigations in Spanish, French, Italian, German—and More Languages on the Horizon

ShadowDragon, a leader in digital investigations and open-source intelligence (OSINT) solutions, today announced the launch of Horizon in multiple languages. Effective immediately, this flagship tool—previously available in English—is now fully localized in Spanish, French, Italian, and German, with additional languages slated for release in the coming months. By expanding language support, ShadowDragon becomes the first in the industry to offer a comprehensive suite of advanced OSINT capabilities designed to serve a wide range of global investigators, law enforcement, and intelligence agencies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207507777/en/

“ShadowDragon has always led the way in building robust OSINT solutions that keep pace with today’s complex global landscape,” said Daniel Clemens, CEO and Founder of ShadowDragon. “By providing our solutions in multiple languages, we reaffirm our commitment to supporting investigations, data scientists, business intelligence, and robust due diligence processes around the world—particularly in regions where language barriers have historically affected use of advanced data visualization tools. We spent a long time building this component to allow analysts to collect, analyze and investigate data and tell the story in their own language.”

Why This Matters for Global Investigations

  1. Accelerated Case Resolution
    With user interfaces, documentation, and workflows now available in Spanish, French, Italian, and German, local and cross-border investigative teams can focus on gathering actionable intelligence — leading to quicker resolutions.
  2. Enhanced Collaboration Across Borders
    International investigations often involve partners from diverse linguistic backgrounds. Harmonizing data and workflows in multiple languages removes communication hurdles, yielding more reliable intelligence and smoother cooperation.
  3. Industry-First Multilingual OSINT Leader
    As the first OSINT provider to fully localize its core offerings across these major languages, ShadowDragon sets a new standard for accessibility and operational readiness in digital investigations.

Commitment to Global Customers

This launch underscores ShadowDragon’s long-term dedication to serving a diverse, international client base that requires cutting-edge OSINT solutions. Users can rely on in-language technical support, ongoing product updates, and comprehensive educational resources to help them get the most out of these new language capabilities from day one.

About ShadowDragon

ShadowDragon provides comprehensive digital tools for modern investigations, open source intelligence collection, tailored monitoring, and investigative platform for cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open-source intelligence (OSINT) from over 200 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for good.”

For more information on ShadowDragon’s multilingual product suite or upcoming language releases, visit www.shadowdragon.io.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250207507777/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye